The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase 1 · 214 people · 13 sites in China · Recruiting now

August 8, 2026
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Phase 3 · 24 people · 1 site in China · Recruiting now

August 8, 2026
Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer

Not phased · randomised · 480 people · 3 sites in 2 countries · Recruiting now

August 8, 2026
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Phase 2 · 25 people · 2 sites in United States · Recruiting now

August 8, 2026
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Phase 2 · 33 people · 1 site in United States · Recruiting now

August 8, 2026
A Study of JMT203 in Patients With Cancer Cachexia

Phase 2 · randomised · 307 people · 1 site in China · Recruiting now

August 8, 2026
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2 · 90 people · 1 site in United States · Recruiting now

August 8, 2026
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer

Phase 2 · 60 people · 1 site in China · Recruiting now

August 8, 2026
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node

Not phased · randomised · 1,384 people · 8 sites in China · Recruiting now

August 8, 2026
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Phase 2 · randomised · 192 people · 1 site in China · Recruiting now

August 8, 2026